A Long-Term Follow-Up Study of Participants Exposed to REACT

Launched by PROKIDNEY · Jun 15, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at the long-term safety of a treatment called REACT for people with chronic kidney disease, which is a condition that affects how well the kidneys function. The study involves participants who have previously received up to two injections of a special gelatin-hydrogel formulation of REACT, spaced three to six months apart. The main goal is to see how these injections impact kidney function over time.

To join this study, participants must have taken part in earlier trials where they received the REACT treatment and completed all required visits. This trial is currently recruiting individuals of all ages, specifically those who are 18 years and older. Participants can expect to have regular check-ups to monitor their kidney health and to provide valuable information that may help improve treatments for chronic kidney disease in the future. If you're interested and meet the criteria, this might be a great opportunity to contribute to important research while keeping an eye on your kidney health.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • The participant must have received gelatin-hydrogel formulation REACT in a previous trial (RMCL-002, REGEN-003, REGEN-004) for the treatment of chronic kidney disease and completed an end of study visit in their parent trial per protocol.
• Exclusion Criteria:
• • The participant did not receive REACT in a previous trial for the treatment of chronic kidney disease.